as on November 6, 2025 at 2:29 am IST
Day's High
3.66%
Upside
52 Week's Low
52 Week's High
32.61%
Downside
102.44%
Upside
Check Atossa Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$109.6M
EPS (TTM)
-0.2467
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
0PEG Ratio
0EBITDA
-30.0M
Revenue (TTM)
-
Profit Margin
0.00%
Return On Equity TTM
-41.66%
Compare market cap, revenue, PE, and other key metrics of Atossa Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $109.6M | -46.96% | NA | 0.00% | |
| BUY | $39.9B | 473.78% | -16.34 | -264.83% | |
| BUY | $55.9B | 232.41% | 1411.57 | 1.36% | |
| BUY | $108.1B | 89.3% | 29.63 | 31.86% | |
| BUY | $67.5B | 11.45% | 15.38 | 32.13% |
The Atossa Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Atossa Therapeutics Inc investment value today
Current value as on today
₹60,441
Returns
Returns from Atossa Therapeutics Inc Stock
Dollar Returns*
₹5,036 (+5.04%)
Based on 10 analysts
90.00%
Buy
10.00%
Hold
0.00%
Sell
Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Atossa Therapeutics Inc. Average target price of $5.69
Get share price movements and forecasts by analysts on Atossa Therapeutics Inc.
What analysts predicted
85.59%UPSIDE
Target Price
$5.69
Current Price
$0.82
Analyzed by
10 Analysts
Target
$5.69
Atossa Therapeutics Inc target price $5.69, a slight upside of 85.59% compared to current price of $0.82. According to 10 analysts rating.
Search interest for Atossa Therapeutics Inc Stock has increased by 110% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:110% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Against Peers
![]()
In the last 1 year, Insmed Incorporated has given 156.5% return, outperforming this stock by 200.6%
Against Peers
![]()
In the last 3 years, Insmed Incorporated has given 926.8% return, outperforming this stock by 930.1%
Price Dip
![]()
In the last 7 days, ATOS stock has moved down by -6.0%
Atossa Therapeutics, Inc., popularly called Atos, is a clinical-stage biopharmaceutical company focused on developing innovative treatments in oncology, particularly for breast cancer. It was founded in 2008 and is headquartered in Seattle, Washington. The company was formerly known as Atossa Genetics Inc. before rebranding to Atossa Therapeutics, Inc. in January 2020.
Atossa develops targeted therapies for breast cancer and related conditions with a focus on areas of unmet medical need. Its lead candidate, oral (Z)-endoxifen, is an active metabolite of tamoxifen currently in Phase II clinical trials for breast cancer treatment and prevention. The company is also advancing immunotherapy programs, including chimeric antigen receptor (CAR) therapies, to expand its pipeline into other oncology areas.
| Products/Programs | Description |
| Oral (Z)-Endoxifen | Phase II-stage drug for treatment and prevention of hormone-receptor positive breast cancer |
| Immunotherapy Programs | Development of CAR-based therapies to target cancerous cells |
| Oncology R&D | Focus on novel, targeted treatments for breast cancer and related indications |
| Clinical Trials | Multiple Phase I/II trials evaluating safety and efficacy of pipeline therapies |
| Organisation | Atossa Therapeutics Inc |
| Headquarters | 107 Spring Street, Seattle, WA, United States, 98104 |
| Industry | Health Technology |
| CEO | Dr. Steven C. Quay FCAP, M.D., Ph.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Mr. Mark Daniel CPA | Chief Financial Officer |
Ms. Janet Rose Rea MSPH, RAC | SVP of R&D |
Ms. Delly Behen P.H.R. | Senior Vice President of Business Operations |
Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President |
Atossa Therapeutics Inc share price today is $0.82 as on at the close of the market. Atossa Therapeutics Inc share today touched a day high of $0.85 and a low of $0.82.
Atossa Therapeutics Inc share touched a 52 week high of $1.66 on and a 52 week low of $0.55 on . Atossa Therapeutics Inc stock price today i.e. is closed at $0.82,which is 50.60% down from its 52 week high and 48.39% up from its 52 week low.
Atossa Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Atossa Therapeutics Inc (ATOS) shares with as little as ₹88.566 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹885.66 in Atossa Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Atossa Therapeutics Inc share’s latest price of $0.82 as on November 6, 2025 at 2:29 am IST, you will get 12.1951 shares of Atossa Therapeutics Inc. Learn more about
fractional shares .
Atossa Therapeutics Inc stock has given -46.96% share price returns and 19.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?